{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121437","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.333432+00:00","generated_at":"2026-05-30T05:15:49.623240+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Syndax Q3 net loss $84.1M; revumenib PDUFA Dec 26; Niktimvo approved; $350M royalty funding","bullets":["Net loss $84.1M ($0.98/share) vs $51.1M ($0.73) in Q3 2023; R&D $71.0M, SG&A $31.1M.","Revumenib NDA under FDA RTOR with PDUFA Dec 26, 2024; topline mNPM1 AML data expected Q4 2024, potential sNDA 1H25.","Niktimvo (axatilimab) approved by FDA for chronic GVHD after ≥2 prior lines; launch early Q1 2025.","$350M royalty funding agreement with Royalty Pharma (13.8% royalty on U.S. Niktimvo sales) expected to fund to profitability.","Full-year 2024 guidance: R&D $245-250M, total op. exp. $365-370M; cash $399.6M as of Sep 30."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121437","json":"https://secwatch.observer/filing/0000950170-24-121437.json","markdown":"https://secwatch.observer/filing/0000950170-24-121437.md","text":"https://secwatch.observer/filing/0000950170-24-121437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024121437/0000950170-24-121437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024121437/sndx-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:15:49.623240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}